Search This Blog

Thursday, August 6, 2026

Testimony of Brian Blase before the Senate Committee on the Budget — Medicaid: The Reality

 

Oral Testimony

Chairman Johnson, Ranking Member Merkley, and Members of the Committee, thank you for the opportunity to testify.

Medicaid is an important welfare program.

But too often, it fails the truly vulnerable—children, pregnant women, the elderly, and people with disabilities.

The federal-state Medicaid partnership is broken.

Over the past dozen years, states have shifted hundreds of billions of Medicaid costs to the federal government.

Washington now pays more than 70 percent of Medicaid spending—up from the historic 60 percent.

I will focus my remarks on two major problems: the Affordable Care Act’s expansion of Medicaid to able-bodied, working-age adults and the legalized money-laundering apparatus that results in massive corporate welfare through Medicaid.

The ACA created a powerful financial incentive for states to prioritize expansion enrollees over traditional enrollees.

On average, when a state spends one dollar of its own money on a traditional Medicaid enrollee—the federal government contributes about $1.33.

But for one dollar of state spending on expansion enrollees, the federal government contributes $9.

Thus, Washington pays states seven times more for each state dollar on expansion adults than for the people Medicaid was created to serve.

Multiple studies show that Medicaid expansion has made it harder for traditional enrollees to obtain physician appointments. It increased wait times and forced more patients to rely on emergency rooms for routine care.

Medicaid should prioritize the most vulnerable. Instead, its financing formula discriminates against them.

These same misguided incentives also explain the surge in improper Medicaid enrollment.

Yesterday, Paragon released a study by Liam Sigaud estimating that nearly half of the 20 million Medicaid expansion enrollees were likely ineligible in 2024. This imposed roughly $33 billion in improper federal costs—with a major cost shift from states to the federal government.

A few states like California and New York have exceptionally high improper enrollment, but the problem exists in virtually all expansion states.

Congress should end the discrimination against the most vulnerable and equalize federal reimbursement rates for all enrollees within each state.

President Obama proposed equalizing reimbursement rates after the ACA became law.

A second major problem is Medicaid money laundering.

The clearest example is provider taxes. Former Oregon State Representative Mitch Greenlick called these dream taxes for states. “We collect the tax from the hospitals, we put it up as a match for federal money, and then we give it back to the hospitals.”

To be clear—this is not a tax. It is a legalized money laundering mechanism for shifting costs from states to Washington, while generating windfalls for politically powerful providers.

In 2011, then-Vice President Joe Biden called provider taxes “a scam” and said that they should be eliminated. Senator Dick Durbin called them “a charade.” The Simpson-Bowles commission, set up by President Obama, recommended ending them.

President Obama proposed limiting provider taxes, and the One Big Beautiful Bill basically adopted his proposal.

Broken Medicaid incentives have led to a new form of corporate welfare: state-directed payments.

Under the Biden administration, CMS allowed Medicaid insurers to pay hospitals up to average commercial rates, or more than two-and-a-half times Medicare.

Medicaid should not pay hospitals more than Medicare. Such excessive Medicaid payments distort the program’s purpose and threaten seniors’ access to care. In the One Big Beautiful Bill, Congress was right to limit Medicaid payments through insurers to Medicare rates.

Most Medicaid spending now runs through health insurance companies, generating enormous revenues for them. Yet, there is remarkably little evidence that Medicaid managed care has improved access, health outcomes, or reduced costs. Increasingly, Medicaid managed care functions as a financing intermediary for corporate welfare.

Medicaid’s perverse incentives have also created a lucrative consulting industry devoted to helping states maximize federal reimbursement by gaming Medicaid’s financing formula rather than improving care.

Medicaid is an essential program. But Congress must improve the core incentives.

Reward states for serving the most vulnerable—not for maximizing federal reimbursement.

End the financial discrimination against the most vulnerable.

Eliminate the money-laundering schemes.

Root out the corporate welfare.

Those reforms will help return balance to the federal-state Medicaid partnership and improve Medicaid for America’s most vulnerable.


https://paragoninstitute.org/private-health/testimony-of-brian-blase-before-the-senate-committee-on-the-budget-medicaid-the-reality/

Older Adults Advised to Limit Anticholinergic Medicines

 Older adults should limit how many anticholinergic medicines they take and use the lowest effective dose for the shortest time needed, the Medicines and Healthcare products Regulatory Agency (MHRA) has advised. The advice follows a safety review of bladder anticholinergic drugs, which found that a small increased risk of dementia cannot be ruled out.

The review found that current evidence is not sufficient to confirm that bladder anticholinergics cause dementia. Taking more than one anticholinergic drug raises the risk of side effects, and ageing reduces the body's ability to process medications, the MHRA said.

Anticholinergics block the action of acetylcholine, whose effects include regulating heartbeat, promoting alertness, and managing bladder activity. Overactive bladder and urinary incontinence are common in dementia. An estimated 53% of people with dementia have incontinence, compared with around 13% of those without dementia. Bladder anticholinergics are a first-line treatment option.

Cognitive Effects 

In the brain, acetylcholine is responsible for nerve communication, memory, and learning. Some symptomatic treatments for Alzheimer’s disease work by boosting acetylcholine levels. The MHRA said that common side effects of anticholinergics include short-term memory loss and confusion, especially among older adults. It is less certain if they have longer-term effects on memory and thinking, including whether their use is linked to an increased risk of dementia. 

However, prolonged exposure has been linked to long-term cognitive decline and dementia incidence among both community living cohorts and nursing home residents. It has been unclear whether the increased risk is specific to the anticholinergic action itself, or due to the underlying conditions for which the drugs were prescribed. Several studies have suggested a specific link between bladder anticholinergics, also called bladder antimuscarinics, and the development of dementia.

Robust Association With Dementia Incidence 

For example, a large case-control study published in The BMJ in 2018 found “a robust association between some classes of anticholinergic drugs and future dementia incidence”. 

The adjusted odds ratio for anticholinergics known to impose the highest cognitive burden was 1.11, and involved antidepressants (predominantly amitriptyline, dosulepin, and paroxetine), urological therapeutics (predominantly oxybutynin and tolterodine), and antiparkinson drugs, but not those used in allergies or gastrointestinal conditions. 

Those affected had used the drugs for between 4 and 20 years before being diagnosed, and risk was greater with longer duration of use. The researchers concluded that the association could have been due to a class-specific effect, or to the drugs being used for very early symptoms of dementia.

A similar study from the Universities of Nottingham, Southampton, and Oxford, published in JAMA Internal Medicine in 2019, found an adjusted odds ratio (OR) for dementia that increased from 1.06 in the lowest overall anticholinergic exposure category to 1.49 in the highest, compared with no anticholinergic drug prescriptions, in the 1-11 years before the index date. There were significant increases in dementia risk for anticholinergic antidepressants (OR, 1.29), antiparkinson drugs (OR, 1.52), antipsychotics (OR, 1.70), bladder antimuscarinics (OR, 1.65), and antiepileptics (OR, 1.39). 

Another study published in Age and Ageing in 2025 found that among prospective cohorts in both the UK Biobank and the US All of Us program, higher use of anticholinergic medications was associated with increased risks of both dementia (hazard ratio [HR], 1.06-1.15) and mortality (HR, 1.16-1.23).

Many Memory Service Patients Have Anticholinergic History 

In a retrospective study from Wales presented at the British Geriatrics Society conference in 2025, a history of anticholinergic prescription was present in 65% of those referred to a memory assessment service.

A review of available data was initiated on the recommendation of the Commission on Human Medicines (CHM), which considered that, generally, it had “low confidence” in the studies. The MHRA examined evidence from marketing authorisation holders, including nonclinical and clinical studies, suspected adverse drug reaction reports submitted through the Yellow Card Scheme, and a critical appraisal of observational studies published since the last review in 2017.

Risk Not Ruled Out 

The MHRA's Public Assessment Report concluded that the available evidence was not sufficient to confirm that bladder anticholinergic medicines directly increase the risk of developing dementia; however, the limitations of these studies meant that a small increased risk could not be completely ruled out.

Considering the strengths and limitations of the available data, the CHM concluded that there remained “considerable uncertainty whether the use of bladder anticholinergics directly increases the risk of developing dementia”. 

It therefore recommended that healthcare professionals should aim to limit the number of anticholinergic medicines older people take, and use the lowest dose for the shortest time needed to control their condition.

https://www.medscape.com/viewarticle/older-adults-advised-limit-anticholinergic-medicines-2026a1000pmy

Oscar Health sinks on potential 2H risks

Oscar Health (OSCR) dived Thursday morning, despite reporting better-than-expected earnings and raising its full-year outlook. OSCR stock initially rallied on the report but later turned sharply lower. The trigger may have been the earnings call discussion about second-half uncertainty regarding Affordable Care Act Marketplace healthcare utilization and associated risk-adjustment payments.

Amylyx nears pivotal avexitide Phase 3 readout, builds PBH launch, extends cash runway into 2028

 


  • Pivotal LUCIDITY Phase 3 in PBH completed visits; top-line data expected late August–early September.
  • Trial powered conservatively at 90% to detect 35% treatment effect despite strong Phase 2.
  • Management targeting 2027 avexitide launch, preparing NDA, commercial infrastructure, and broad education campaign for PBH.
  • U.S. PBH prevalence estimated 160k, with ~120k Roux-en-Y patients comprising meaningful initial commercial population.
  • Early Access Program started for prior avexitide trial participants; early enthusiasm reported, but no quantitative metrics disclosed.
  • Q2 2026 cash and securities $250.8M, providing runway into 2028 through anticipated avexitide approval and launch.
  • Q2 2026 non-GAAP EPS -$0.39 (+15% YoY) with net loss $43.4M.
  • Q2 operating expenses $45.7M, up 7% YoY; R&D declined while SG&A rose on legal and commercial spend.
  • New ICD-10 code for PBH effective October 2026 should aid recognition, coding, and patient identification.
  • Pipeline advancing: AMX0114 ALS Phase 1, AMX0035 Wolfram moving toward Phase 3, AMX0318 IND in 2027.
  • Management tone confident on avexitide profile and unmet need; company entering quiet period ahead of data.
  • Main concern: binary avexitide Phase 3 outcome and potential initial label restrictions remain key risks.
  • Strong quarter supported by disciplined spending, ample cash runway, and progress toward avexitide Phase 3 data and commercialization.

Sotera Health beats, ups outlook

 

Sotera Health beats Q2 2026 EPS and revenue estimates with non-GAAP EPS $0.26, revenue $321.4M, raises 2026 revenue, EBITDA and EPS outlook

  • Q2 exceeded internal expectations with 8% constant-currency revenue and margin expansion companywide.
  • Sterigenics and Nordion delivered high-single to mid-teens growth, offsetting Nelson Labs cost pressure.
  • Management raised 2026 revenue, EBITDA and EPS guidance slightly, citing stronger Sterigenics second-half outlook.
  • Sterigenics volume growth, new X-ray facility ramp, and large EO outsourcing contract underpin confidence.
  • Capex increased to $200–$225 million for growth and EO upgrades, and 2027 step-down was reaffirmed.
  • Balance sheet reached 3x net leverage target, interest expense outlook and tax rate both improved.
  • EO litigation and regulatory backdrop remain main overhang, with immaterial New Mexico settlement, progressing Georgia appeal, limited near-term financial impact.
  • New CEO prioritizing customer focus, cross-business 'One Sotera' offerings, and disciplined capital deployment.
  • Strong quarter, driven by Sterigenics and Nordion outperformance plus higher 2026 guidance and margins.

'AP: Testing Underway on Vaccines to Intercept Brewing Colon Cancer Before It Takes Root'

 Stacy Norton, MD, was only 7 years old when her mother died of colon cancer, one of several family members struck by aggressive tumors at unusually young ages. Decades later, Norton rolled up her sleeve to help test if a new kind of vaccine might protect her and her own children from cancer.

The Houston doctor is among an estimated 1 million Americans who have Lynch syndrome, a faulty gene passed from a parent that puts them at extremely high risk of colorectal cancer and more vulnerable to certain other cancers, too. They're often urged to get yearly colonoscopies -- far more often than usual -- that can spot and remove precancerous polyps.

Now scientists are creating vaccines that aim to go further, teaching the immune system to intercept this type of brewing colon cancer before it turns into a full-fledged tumor. At least three potential Lynch syndrome vaccines are in development, including two in early clinical trials in the U.S. and a third beginning in Britain.

The shot that Norton helped test appears promising enough that its lead researcher, Eduardo Vilar-Sanchez, MD, PhD, of the University of Texas MD Anderson Cancer Center in Houston, expects a larger study to begin early next year.

"It gives me hope," said Norton, 59, of Houston Methodist Willowbrook Hospital. She had already survived a different Lynch-caused cancer and has two children in their 20s who inherited her mutation. If a vaccine pans out, "perhaps they won't have to have a colonoscopy every single year for the rest of their lives."

Lynch Syndrome Is Caused by an Inherited Genetic Mutation

Everyone has mismatch-repair genes, which are essentially spellcheckers to help fix DNA mistakes that can occur when our cells multiply. With Lynch syndrome, one of those genes can't do its job properly, making it harder for the body to stop a buildup of abnormalities that can lead to tumors, often before age 50.

Colorectal cancer is the most common consequence. The average person has a 5% risk of developing it during their lifetime. A Lynch carrier's risk can reach as high as 80% depending on which faulty gene they inherit, Vilar-Sanchez said.

Another big risk is endometrial, or uterine, cancer. Lynch carriers also are more likely to get other cancers including pancreatic, stomach, ovarian, and certain skin cancers -- and a kind of brain tumor that killed Norton's sister at age 25.

Norton knew some of her mother's relatives had also experienced colon cancer, but she was in her 40s before a gene test confirmed she has Lynch syndrome. She switched from every-so-often to yearly colonoscopies. As an obstetrician/gynecologist familiar with other Lynch risks, Norton also decided to have a precautionary hysterectomy. Surgeons discovered early-stage cancer in her removed uterus.

Possible Vaccines to Stop Gene-Caused Cancer

Today there are two cancer-preventing vaccines, the human papillomavirus (HPV) and hepatitis B shots that block infection from those tumor-causing viruses. But developing vaccines to prevent gene-caused cancer is more challenging than alerting the body to foreign intruders like a virus.

Lynch-fueled growths "tend to accumulate hundreds of mutations that are going to generate proteins that are novel, not made by our normal cells," Vilar-Sanchez said. "You can train the immune system to recognize those proteins."

In a first-step study, Norton and 44 other Lynch carriers tested a vaccine made by Swiss biotech Nouscom that teaches the immune system to spot 209 of those abnormalities in Lynch-caused precancers. That revved up tumor-eliminating T cells, and a year later, colonoscopies showed fewer precancerous growths and no advanced polyps, the MD Anderson team reported in Nature Medicine.

"Can we even further stimulate the immune system" to keep up with Lynch syndrome-spurred tumor formation, asked John Marshall, MD, a Georgetown University oncologist and adviser to the Colorectal Cancer Alliance who wasn't involved with the study. "This early paper suggests that yeah, maybe we can."

For the first time since 2014, Norton's own colonoscopies 1 and 2 years after vaccination were polyp-free. She's also part of a subset of study participants given a booster shot a year later; more data on that are expected this fall.

Oxford University researchers are also beginning initial testing of a similar approach to attack Lynch-spurred precancers, a vaccine made by Massachusetts-based Moderna using the mRNA technology behind its COVID-19 shot.

And scientists are awaiting results from a slightly larger study comparing California-based ImmunityBio's Tri-Ad5 vaccine, which flags some different cancer markers, to a placebo.

Is Lynch Syndrome Tied to the Rise in Young Adult Colon Cancer?

About 158,000 people are diagnosed with colorectal cancer in the U.S. each year, most of them over 50. Cases in younger adults are increasing, though it isn't clear why.

Lynch syndrome affects about 1 in 279 people. While most don't know it, more may be learning they have the inherited disorder, Vilar-Sanchez said, as genetic testing is increasingly discussed with people with Lynch-related cancer in the family or who get certain tumors at young ages. That in turn can show if close relatives might also be at risk.

For the average person, U.S. guidelines call for routine colorectal cancer screening -- with a colonoscopy or other kinds of tests -- to begin at age 45. But at any age, get a checkup for symptoms such as blood in stool or rectal bleeding; changes in bowel habits such as diarrhea, constipation, or narrowing of stool that lasts more than a few days; unintended weight loss; and cramps or abdominal pain.

https://www.medpagetoday.com/gastroenterology/coloncancer/122510

3 Factors Tied to 13 Additional Dementia-Free Years

 

  • Midlife vascular health was associated with nearly 13 more dementia-free years in a prospective U.S. cohort study.
  • At age 55, healthier study participants averaged 30.1 additional years without dementia.
  • Smoking, hypertension, and diabetes together sharply increased dementia risk and mortality.

Maintaining three key health factors during midlife -- normal blood pressure, no diabetes, and not smoking -- was associated with nearly 13 additional dementia-free years, a study of 12,000 people in the U.S. showed.

Individuals who met these criteria at age 55 lived an average 30.1 more years dementia-free, reported Josef Coresh, MD, PhD, of NYU Langone Health in New York City, and co-authors.

Conversely, those who smoked, had hypertension, and had diabetes at age 55 had dementia-free survival of only 17.5 years, Coresh and colleagues wrote in Neurology Open Access.

People with all three risk factors had a higher incidence of dementia (HR 2.69, 95% CI 1.94-3.73) and a higher incidence of dying before a dementia diagnosis (HR 5.61, 95% CI 4.67-6.74) compared with those who had no risk factors.

Overall, women lived longer without dementia than men at all risk levels. White participants had more years free of dementia than Black participants, and APOE4 carriers had shorter dementia-free survival than noncarriers.

"Our findings argue that people need to actively avert these factors in midlife as a strategy for preserving brain health for more than a decade," Coresh said in a statement. "Discovering new ways to delay dementia is crucial with 42% of Americans at risk for developing the condition at any time after age 55."

The findings were based on 12,409 participants in the prospective Atherosclerosis Risk in Communities (ARIC) study, which started in 1986 to evaluate midlife vascular risk factors and late-life dementia.

Previous research from the ARIC cohort suggested that 22% to 44% of dementia risk by age 80 could be attributed to three vascular risk factors measured in midlife and early late life, after accounting for risk factor concurrence and interactions.

Hypertension was defined as systolic blood pressure ≥130 mm Hg, diastolic blood pressure ≥80 mm Hg, or the use of blood pressure medication; diabetes as fasting glucose ≥126 mg/dL, non-fasting glucose ≥200 mg/dL, a physician's diagnosis, or the use of any diabetes medication; and current smoking was self-reported.

"Our study complements this important work by shifting focus from probability-based and attributable risk metrics to a time-based estimand -- dementia-free survival years, which quantifies the expected duration of life lived cognitively intact," Coresh and colleagues wrote.

"This outcome integrates two clinically relevant processes: incident dementia and death before dementia, therefore reflecting the competing risks that shape real-world aging trajectories," they pointed out. "In contrast to previous ARIC studies, this framework emphasizes how vascular health influences the balance between longevity and cognitive health over the life course."

In the current analysis, ARIC participants had a mean baseline age of 56 and 56% were women. Dementia was tracked through cognitive assessments, informant interviews, and continuous surveillance. Deaths without dementia were captured from multiple sources including the National Death Index.

Over a median follow-up of 26.3 years, 3,008 cases of dementia and 5,238 deaths without dementia were documented. Better vascular health was linked with longer dementia-free survival in a dose-response pattern.

"Several biologic pathways likely underlie our observed associations between vascular health and dementia-free survival, including chronic cerebrovascular injury, neuroinflammation triggered by vascular damages through hypertension and diabetes, and cumulative oxidative stress resulting from smoking," Coresh and colleagues wrote. "Together, these factors likely accelerate atherosclerosis, increase stroke risk, and may facilitate Alzheimer's disease pathology through promoting amyloid plaques and tau tangles."

The findings relied on one midlife assessment of risk factors, the researchers acknowledged. Dementia ascertainment may have differed between participants who attended recent visits and those who didn't. In addition, the study was observational and residual confounding may have influenced outcomes.

Disclosures

This research was supported by the NIH and the National Natural Science Foundation of China.

Coresh and co-authors had no conflicts of interest.